Celgene Co. (CELG) Shares Sold by Axa
Axa decreased its holdings in Celgene Co. (NASDAQ:CELG) by 6.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,174,479 shares of the biopharmaceutical company’s stock after selling 80,935 shares during the quarter. Celgene comprises about 0.7% of Axa’s investment portfolio, making the stock its 17th biggest holding. Axa’s holdings in Celgene were worth $171,262,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Thompson Davis & CO. Inc. increased its position in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI increased its position in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares in the last quarter. Robecosam AG purchased a new position in shares of Celgene in the third quarter valued at $114,000. Guidant Wealth Advisors purchased a new position in shares of Celgene in the third quarter valued at $119,000. Finally, Capital Bank & Trust Co increased its position in shares of Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares in the last quarter. Hedge funds and other institutional investors own 78.93% of the company’s stock.
Shares of Celgene Co. (NASDAQ CELG) opened at $95.16 on Thursday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Co. has a 52 week low of $92.85 and a 52 week high of $147.17. The stock has a market capitalization of $74,920.00, a PE ratio of 26.36, a price-to-earnings-growth ratio of 0.67 and a beta of 1.49.
CELG has been the topic of a number of analyst reports. Mizuho reaffirmed a “buy” rating and set a $128.00 price objective on shares of Celgene in a research note on Sunday. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price objective on shares of Celgene in a research note on Monday, January 29th. SunTrust Banks reaffirmed a “buy” rating and set a $139.00 price objective (up previously from $127.00) on shares of Celgene in a research note on Friday, January 26th. Finally, Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective on the stock in a research note on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and a consensus target price of $130.35.
COPYRIGHT VIOLATION WARNING: “Celgene Co. (CELG) Shares Sold by Axa” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/02/08/celgene-co-celg-shares-sold-by-axa.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.